CD22 and lymphoma: Anti-CD19 cord blood (CB)-derived NK cells were evaluated in a xenograft lymphoma murine model and significantly prolonged the survival of mice.442 In another study, anti-CD5 CAR-NKs had potent antitumor activity against a variety of T-NHLs and primary tumor cells in vitro and in a murine model.443 Clinical trials (NCT03383965, NCT029170083 and NCT03049449) of CAR-NK cells targeting CD19, CD20, and CD22 have begun for the treatment of B-NHLs.